Subtopic Deep Dive
Preexposure Prophylaxis
Research Guide
What is Preexposure Prophylaxis?
Preexposure Prophylaxis (PrEP) uses antiretroviral drugs like tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) to prevent HIV acquisition in high-risk individuals before exposure.
PrEP efficacy was first demonstrated in men who have sex with men (MSM) with 92% protection when FTC-TDF levels were detectable (Grant et al., 2010, 5029 citations). Trials extended efficacy to heterosexuals (Baeten et al., 2012, 3229 citations; Thigpen et al., 2012, 1994 citations). Over 15 key trials from 2008-2021 report adherence as the primary efficacy driver.
Why It Matters
PrEP reduces new HIV infections by up to 99% with high adherence in MSM (Grant et al., 2010), enabling targeted rollout in high-prevalence communities like sub-Saharan Africa (Thigpen et al., 2012). Long-acting cabotegravir injections outperform daily TDF-FTC in MSM and transgender women (Landovitz et al., 2021). Real-world implementation cuts transmission in MSM epidemics (McCormack et al., 2015). Guidelines recommend PrEP for all high-risk adults (Günthard et al., 2016).
Key Research Challenges
Adherence in Women
Low adherence undermined PrEP efficacy in African women, with no reduction in HIV acquisition despite TDF-FTC (Marrazzo et al., 2015). Detectable drug levels correlated weakly with protection across populations (Grant et al., 2010). Behavioral and structural factors drive non-adherence.
Long-term Safety
Daily TDF-FTC raises concerns for bone mineral density loss and renal effects (Thigpen et al., 2012). On-demand dosing increased gastrointestinal and renal events (Molina et al., 2015). Monitoring protocols remain undefined for extended use.
Resistance Development
INSTI resistance emerged in cabotegravir PrEP failures (Landovitz et al., 2021). Breakthrough infections risk selecting resistant HIV strains (Marrazzo et al., 2015). Strategies for failure cases need refinement.
Essential Papers
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant, Javier R. Lama, Peter L. Anderson et al. · 2010 · New England Journal of Medicine · 5.0K citations
Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Insti...
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
Jared M. Baeten, Deborah Donnell, Patrick Ndase et al. · 2012 · New England Journal of Medicine · 3.2K citations
Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women. (Funded by the Bill and Melinda Gates Foundation; Partners PrEP ClinicalTrials.gov number, NCT00557245.).
Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana
Michael C. Thigpen, Poloko Kebaabetswe, Lynn Paxton et al. · 2012 · New England Journal of Medicine · 2.0K citations
Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults. The long-term safety of daily TDF-FTC prophylaxis, including the effect on bone mineral density, remains un...
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Sheena McCormack, David Dunn, Monica Desai et al. · 2015 · The Lancet · 1.9K citations
MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Jean‐Michel Molina, Catherine Capitant, Bruno Spire et al. · 2015 · New England Journal of Medicine · 1.6K citations
The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal a...
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne Marrazzo, Gita Ramjee, Barbra A. Richardson et al. · 2015 · New England Journal of Medicine · 1.3K citations
None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOIC...
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Ayesha B. M. Kharsany, Quarraisha Abdool Karim · 2016 · The Open AIDS Journal · 953 citations
Global trends in HIV infection demonstrate an overall increase in HIV prevalence and substantial declines in AIDS related deaths largely attributable to the survival benefits of antiretroviral trea...
Reading Guide
Foundational Papers
Start with Grant et al. (2010) for MSM proof-of-concept (92% efficacy with adherence); Baeten et al. (2012) and Thigpen et al. (2012) for heterosexual validation.
Recent Advances
Landovitz et al. (2021) for cabotegravir superiority; McCormack et al. (2015) for real-world on-demand PrEP effectiveness.
Core Methods
Daily TDF-FTC (Grant et al., 2010), on-demand dosing (Molina et al., 2015), long-acting cabotegravir injections (Landovitz et al., 2021), with tenofovir level monitoring for adherence.
How PapersFlow Helps You Research Preexposure Prophylaxis
Discover & Search
Research Agent uses searchPapers('PrEP adherence women') to find Marrazzo et al. (2015), then citationGraph reveals 1274 citing papers on adherence barriers, and findSimilarPapers surfaces Baeten et al. (2012) for comparative efficacy across genders.
Analyze & Verify
Analysis Agent runs readPaperContent on Grant et al. (2010) to extract adherence-protection correlations, verifies claims via verifyResponse (CoVe) against Thigpen et al. (2012), and uses runPythonAnalysis for GRADE grading of trial evidence quality with statistical meta-analysis of risk ratios.
Synthesize & Write
Synthesis Agent detects gaps in long-acting PrEP adherence data post-Landovitz et al. (2021), flags contradictions between daily vs. on-demand regimens from Molina et al. (2015), while Writing Agent applies latexEditText, latexSyncCitations for Grant et al. (2010), and latexCompile for trial comparison tables with exportMermaid flowcharts.
Use Cases
"Meta-analyze PrEP adherence rates from major trials using Python."
Research Agent → searchPapers('PrEP trials adherence') → Analysis Agent → runPythonAnalysis(pandas meta-analysis of hazard ratios from Grant 2010, Baeten 2012, Marrazzo 2015) → outputs CSV of pooled risk reductions with confidence intervals.
"Draft LaTeX review comparing TDF-FTC vs cabotegravir PrEP."
Synthesis Agent → gap detection (adherence gaps) → Writing Agent → latexEditText(structured sections), latexSyncCitations(Grant 2010, Landovitz 2021), latexCompile → researcher gets compiled PDF with cited trial tables.
"Find code for PrEP pharmacokinetic modeling from papers."
Research Agent → paperExtractUrls(Grant 2010) → paperFindGithubRepo(pharmacokinetic models) → githubRepoInspect → outputs runnable Python scripts for tenofovir level simulations tied to protection efficacy.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ PrEP papers: searchPapers → citationGraph(Grant 2010 cluster) → GRADE grading → structured report on efficacy by population. DeepScan applies 7-step analysis with CoVe checkpoints to verify adherence data from Marrazzo et al. (2015) against Baeten et al. (2012). Theorizer generates hypotheses on resistance prevention from Landovitz et al. (2021) failures.
Frequently Asked Questions
What is the definition of Preexposure Prophylaxis?
PrEP administers antiretrovirals like TDF-FTC before HIV exposure to prevent infection in high-risk groups (Grant et al., 2010).
What methods prove PrEP efficacy?
Randomized trials show 92% protection in MSM with detectable FTC-TDF (Grant et al., 2010), 75% in heterosexuals (Baeten et al., 2012), and superiority of cabotegravir injections (Landovitz et al., 2021).
What are key PrEP papers?
Grant et al. (2010, 5029 citations) established MSM efficacy; Baeten et al. (2012, 3229 citations) heterosexuals; Landovitz et al. (2021, 757 citations) long-acting formulations.
What open problems remain in PrEP?
Adherence failures in women (Marrazzo et al., 2015), long-term bone/renal safety (Thigpen et al., 2012), and INSTI resistance strategies (Landovitz et al., 2021).
Research HIV/AIDS Research and Interventions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Preexposure Prophylaxis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers